Oxytocin Antagonist in Patients With Repeated Failure of Implantation

Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01673399

Enrollment

138

Registered

2012-08-28

Start date

2012-02-29

Completion date

2015-02-28

Last updated

2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Implantation Failure

Keywords

repeated implantation failure (RIF), atosiban, pregnancy

Brief summary

In this study the investigators compare the usual way of embryo transfer (without medication) with an embryo transfer while administering oxytocine antagonist. This to improve implantation and increase the pregnancy rate.

Interventions

DRUGAtosiban

Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Inclusion criteria

* IVF/ ICSI patients below 38 years * 2e to 6e IVF-cycle

Exclusion criteria

* patients with endocrinological diseases or problems

Design outcomes

Primary

Measure	Time frame	Description
implantation rate	16 days from eggretrieval	the number of patients that show a positive serum blood pregnancy test

Secondary

Measure	Time frame	Description
pregnancy rate	12 weeks	The number of patients with an ongoing first trimester pregnancy

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026